{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:17:56Z","timestamp":1778069876938,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clml.2026.03.001","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:21:41Z","timestamp":1772731301000},"page":"e690-e698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Treatment of Double Refractory Chronic Lymphocytic Leukemia: A Focus on Novel Drugs"],"prefix":"10.1016","volume":"26","author":[{"given":"Evani","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiranjeevi","family":"Sainatham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prithvi","family":"Raghavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anirudh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Forat","family":"Lutfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.clml.2026.03.001_bib0001","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"10277","key":"10.1016\/j.clml.2026.03.001_bib0002","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.clml.2026.03.001_bib0003","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.001_bib0004","first-page":"1640","article-title":"Epcoritamab in relapsed or refractory chronic lymphocytic leukemia: results from the dose escalation part of the phase 1\/2 EPCORE CLL-1 trial","volume":"142","author":"Davids","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.001_bib0005","first-page":"7501","article-title":"Safety and efficacy of liso-cel in relapsed or refractory (R\/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL): TRANSCEND CLL 004 study","volume":"40","author":"Shadman","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clml.2026.03.001_bib0006","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/bloodadvances.2020001956","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents","volume":"4","author":"Roeker","year":"2020","journal-title":"Blood Adv"},{"issue":"9747","key":"10.1016\/j.clml.2026.03.001_bib0007","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"The Lancet"},{"issue":"17","key":"10.1016\/j.clml.2026.03.001_bib0008","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1002\/cncr.28030","article-title":"Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center","volume":"119","author":"Falchi","year":"2013","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.clml.2026.03.001_bib0009","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2024025482","article-title":"How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor","volume":"146","author":"Shadman","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2026.03.001_bib0010","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.3109\/10428194.2012.695781","article-title":"Targeting the B cell receptor pathway in chronic lymphocytic leukemia","volume":"53","author":"Davids","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2026.03.001_bib0011","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2026.03.001_bib0012","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2026.03.001_bib0013","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.clml.2026.03.001_bib0014","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus Ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2026.03.001_bib0015","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.03.001_bib0016","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.clml.2026.03.001_bib0017","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2026.03.001_bib0018","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3390\/ijms25031589","article-title":"Treatment of double-refractory chronic lymphocytic leukemia-an unmet clinical need","volume":"25","author":"Zygmunciak","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.clml.2026.03.001_bib0019","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"14","key":"10.1016\/j.clml.2026.03.001_bib0020","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","article-title":"Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy","volume":"26","author":"Mato","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.clml.2026.03.001_bib0021","first-page":"2093","article-title":"Efficacy of therapies following venetoclax discontinuation in CLL: focus on B-cell receptor signal transduction inhibitors and cellular therapies","volume":"138","author":"Mato","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.03.001_bib0022","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","article-title":"Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2026.03.001_bib0023","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 621 ibrutinib- treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.clml.2026.03.001_bib0024","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.03.001_bib0025","series-title":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (Version 1.2025)","year":"2024"},{"key":"10.1016\/j.clml.2026.03.001_bib0026","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2026.03.001_bib0027","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2026.03.001_bib0028","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJMoa2515458","article-title":"Fixed-duration versus continuous treatment for chronic lymphocytic leukemia","volume":"394","author":"Al-Sawaf","year":"2026","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2026.03.001_bib0029","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/bloodadvances.2024014474","article-title":"Consensus recommendations from the 2024 Lymphoma Research Foundation Workshop on chronic lymphocytic leukemia","volume":"9","author":"Stephens","year":"2025","journal-title":"Blood Adv"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.001_bib0030","first-page":"7519","article-title":"Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL\/SLL: updated results from the phase 1\/2 BRUIN study","volume":"40","author":"Mato","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2026.03.001_bib0031","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2019-127260","article-title":"Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.001_bib0032","first-page":"7512","article-title":"Pirtobrutinib and prior BCL2 inhibitor exposure in CLL: long-term follow-up from the BRUIN study","volume":"42","author":"Mato","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.001_bib0033","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3324\/haematol.2022.281266","article-title":"PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?","volume":"108","author":"Sk\u00e5nland","year":"2022","journal-title":"Haematologica"},{"issue":"10402","key":"10.1016\/j.clml.2026.03.001_bib0035","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clml.2026.03.001_bib0036","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1093\/oncolo\/oyad324","article-title":"Treatment patterns, healthcare resource utilization, and costs of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the US","volume":"29","author":"Yang","year":"2024","journal-title":"Oncologist"},{"issue":"35","key":"10.1016\/j.clml.2026.03.001_bib0037","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1080\/14796694.2024.2390351","article-title":"Healthcare resource utilization and costs of chronic lymphocytic leukemia\/small lymphocytic lymphoma patients who relapse or are refractory to ibrutinib","volume":"20","author":"De Nigris","year":"2024","journal-title":"Future Oncol."},{"issue":"24","key":"10.1016\/j.clml.2026.03.001_bib0038","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2026.03.001_bib0039","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: second-generation drugs and beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2026.03.001_bib0040","first-page":"612","article-title":"Novel mechanisms of BTK inhibitor resistance in chronic lymphocytic leukemia: insights from single-cell analysis","volume":"38","author":"Chen","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2026.03.001_bib0041","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood.2024027009","article-title":"Genomic determinants of response and resistance to pirtobrutinib in relapsed\/refractory chronic lymphocytic leukemia","volume":"147","author":"Brown","year":"2026","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.03.001_bib0042","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.001_bib0043","article-title":"Mechanisms of venetoclax resistance in chronic lymphocytic leukemia: beyond BCL2 mutations","volume":"63","author":"Chen","year":"2024","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.clml.2026.03.001_bib0044","first-page":"876","article-title":"Evolutionary trajectories of chronic lymphocytic leukemia under therapeutic pressure: implications for personalized medicine","volume":"30","author":"Landau","year":"2024","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.001_bib0045","first-page":"1638","article-title":"Clinical activity of NX-2127, a novel degrader of BTK with immunomodulatory activity, in patients with relapsed\/refractory B-cell malignancies","volume":"142","author":"Soumerai","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.001_bib0046","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2025-86","article-title":"Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed\/refractory chronic lymphocytic leukemia (CLL): new and updated findings from an ongoing phase 1a\/b trial","volume":"146","author":"Omer","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.03.001_bib0047","first-page":"1056","article-title":"Promising results in difficult-to-treat CLL with epcoritamab: updated results from the EPCORE CLL-1 trial","volume":"145","author":"Davids","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.001_bib0048","doi-asserted-by":"crossref","first-page":"6804","DOI":"10.1182\/blood-2024-193052","article-title":"Future landscapes of bispecific antibodies in chronic lymphocytic leukemia: a systematic review of clinical trials","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2026.03.001_bib0050","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2024-200339","volume":"144","author":"Wierda","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.001_bib0051","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood-2025-798","article-title":"Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia","volume":"146","author":"Huang","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.03.001_bib0052","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood.2024027460","article-title":"ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"146","author":"Davids","year":"2025","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2026.03.001_bib0053","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.2023019706","article-title":"Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy","volume":"143","author":"Liu","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.001_bib0054","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2025-2137","volume":"146","author":"Al-Sawaf","year":"2025","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2026.03.001_bib0055","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 inhibitors for hematologic malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2026.03.001_bib0056","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood.2024024510","article-title":"Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed\/refractory CLL: the phase 1b BRUIN trial","volume":"144","author":"Roeker","year":"2024","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2026.03.001_bib0057","first-page":"1213","article-title":"Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukaemia","volume":"145","author":"Grainger","year":"2025","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:40:06Z","timestamp":1778067606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2152265026000650"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Treatment of Double Refractory Chronic Lymphocytic Leukemia: A Focus on Novel Drugs","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}